CanSight Corporation: Innovative glaucoma drug Tafluprost eye drops Teprokan listed in China.

CanSight Corporation recently announced that their sodium fluorescein eye drops, Taipukang, have officially launched in China. Taipukang is the first original eye drop formulation in China containing a prostaglandin derivative as a first-line treatment for glaucoma, without preservatives. It is used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension who have ineffective treatment with -blockers or prostaglandin derivatives alone and require combination therapy, as well as in patients who may benefit from preservative-free eye drops.